Portland, OR -- (SBWIRE) -- 01/09/2018 -- Naltrexone HCL, an opioid antagonist, is a synthetic congener of oxymorphone with no opioid agonist properties. It markedly reduces or completely blocks, reversibly, the subjective effects of intravenously administered opioids. This drug is generally administered orally to treat alcohol dependence. The growing cases of alcohol dependence with increasing consumption of alcohol worldwide create a need for Naltrexone HCL.

Access Full Summary@ https://www.alliedmarketresearch.com/naltrexone-HCL-market

The market is mainly driven by increasing alcohol dependency worldwide. According to the 2015 National Survey on Drug Use and Health (NSDUH), 7% of the population was reported that they were engaged in heavy alcohol use. Such high prevalence of alcohol dependency is expected to drive the market during the forecast period. However, the side effects of the drug such as nausea and others may restrict the growth of the naltrexone HCL market.

The report segments the market on the basis of type, application, and geography. Based on type the market is segmented into medical grade and others. By application the market is categorized into opioid independence, alcohol independence, and other. A geographic breakdown and deep analysis of each of the aforesaid segments have been covered for North America, Europe, Asia-Pacific, and LAMEA.

Comprehensive competitive analysis and profiles of major market players such as Teva Pharmaceutical Industries Ltd., Ascent Scientific Ltd., Adooq Bioscience LLC, Mallinckrodt Pharmaceuticals, and Sun Pharmaceutical Industries Limited, and others have been provided in this report.

Get Sample PDF of the Report@ https://www.alliedmarketresearch.com/request-toc-and-sample/3660

Naltrexone HCLMarket Key Segments:

By Type

-Medical Grade
-Others

By Applications

-Opioid Independence
-Alcohol Independence
-Other